Research Project

Project Title:	A multicenter, randomized, double-blind, parallel group, placebo-controlled study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of BI 764198 administered orally once daily for 12 weeks in patients with focal segmental glomeruloscle
Project Type:	Clinical Trial, Enrolment terminated
Disease group(s):	Immune glomerulopathies
Project Summary:	A multicenter, randomized, double-blind, parallel group, placebo-controlled study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of BI 764198 administered orally once daily for 12 weeks in patients with focal segmental glomerulosclerosis.
Lead principal investigator(s):	Bologna La Manna, Bologna
Co-investigator(s):	, Francesco Tondolo, Bologna Elisa Gessaroli, Bologna
Project Period:	09/2022 - 12/2024
Sponsors:	Industry